Chen Man, Wang Aixian, Liu Shuqiang, Wu Xueying, Gong Meiwei, Zhen Junyi, Fu Minjing, Wang Hui
Department of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, No.2 Siplan Road, Yanjiao Development Zone, Langfang, 065201 Hebei China.
Tianjin Mycure Medical Technology Co., Ltd., Wuqing, 301700 Tianjin China.
Indian J Hematol Blood Transfus. 2021 Apr;37(2):271-279. doi: 10.1007/s12288-020-01357-x. Epub 2020 Sep 24.
T cell therapy represents a new class of immunotherapies garnering considerable attention. T cell receptor beta chain constant region 1 (TRBC1) is partially expressed in subsets of normal T cells. However, the immunotherapy of T lymphocyte tumors is rarely validated in clinical trials. Here, we aim to explore whether TRBC1 is a promising target for the immunotherapy of T lymphocyte tumors. This study examined TRBC1 expression in 25 healthy bone marrow samples, 39 patients with T-lineage acute lymphocytic leukemia (T-ALL), 4 patients with mature T cell neoplasms, and 5 patients suspected with mature T cell neoplasms with evidence of T cell neoplasia. Moreover, the expression of TRBC1 was evaluated by flow cytometry and through PCR detection of TCR gene rearrangements. The expression of monophasic TRBC1 was identified in all 25 normal bone marrows (23.83% ± 2.74% positive rate). The expression of TRBC1 was positive in 5 patients (12.8%) among the 39 T-ALL patients. TRBC1 was partially expressed in 1 patient (25%) with T cell non-Hodgkin's lymphoma (T-NHL) and in 1 patient (20%) suspected to have T-NHL. Healthy donors showed a pattern of partial expression and patients with T-lymphocyte tumors showed a polytypic TRBC1 expression pattern. Thus, TRBC1 may be a diagnostic and therapeutic marker for T lymphocyte tumors.
T细胞疗法是一类备受关注的新型免疫疗法。T细胞受体β链恒定区1（TRBC1）在正常T细胞亚群中部分表达。然而，T淋巴细胞肿瘤的免疫疗法在临床试验中很少得到验证。在此，我们旨在探讨TRBC1是否是T淋巴细胞肿瘤免疫疗法的一个有前景的靶点。本研究检测了25份健康骨髓样本、39例T系急性淋巴细胞白血病（T-ALL）患者、4例成熟T细胞肿瘤患者以及5例疑似成熟T细胞肿瘤且有T细胞肿瘤证据患者的TRBC1表达。此外，通过流式细胞术和TCR基因重排的PCR检测评估TRBC1的表达。在所有25份正常骨髓中均鉴定出单相TRBC1的表达（阳性率为23.83%±2.74%）。39例T-ALL患者中有5例（12.8%）TRBC1表达呈阳性。TRBC1在1例T细胞非霍奇金淋巴瘤（T-NHL）患者（25%）和1例疑似T-NHL患者（20%）中部分表达。健康供体表现出部分表达模式，而T淋巴细胞肿瘤患者表现出多型性TRBC1表达模式。因此，TRBC1可能是T淋巴细胞肿瘤的诊断和治疗标志物。
